Health•General

HIV injections keep virus suppressed better than daily pills: Study

ANI|
Updated: Sep 20, 2026 15:42 IST
Verified Report
Share Story:
HIV injections keep virus suppressed better than daily pills: Study

Representative Image (Photo/unsplash)

Get the fastest news alerts directly on your WhatsApp.
Join WhatsApp Channel
Washington [US], September 20 (ANI): Eight-weekly HIV injections kept the virus suppressed more effectively than daily tablets among adolescents in an African clinical trial, with researchers calling for wider access to the treatment in low- and middle-income settings.
The study published by Eureka Alert!, young people living with HIV managed their treatment better with long-acting injections given every eight weeks than with daily antiretroviral tablets, according to a trial led by researchers at University College London (UCL).
The findings, published in The Lancet, showed that only two adolescents, or 1 per cent, receiving the injectable treatment experienced confirmed viral rebound after 96 weeks, compared with 15, or 6 per cent, among those taking daily tablets.
The LATA (Long-Acting Treatment in Adolescents) trial involved 476 adolescents aged 12 to 19 across five clinics in Kenya, South Africa, Uganda and Zimbabwe. Participants were randomly assigned either standard daily tablet treatment or injections containing the long-acting HIV medicines cabotegravir and rilpivirine.
All participants had been taking tablet treatment for more than a year, had fully suppressed HIV and had no previous treatment failure. Almost all had acquired HIV at birth.
Viral rebound refers to an increase in the amount of HIV in the blood after the virus had been suppressed. The researchers noted that rising viral loads can affect long-term health and, in some cases, increase the risk of transmission.
Nearly all participants in the injectable group- 94 per cent- said receiving treatment every eight weeks was much easier than taking medicines every day.
Professor Sarah Pett of the UCL Innovative Clinical Trials Unit, chief investigator of the LATA trial, said, “HIV-positive adolescents as a group have historically done worse on antiretrovirals compared to adults. There is bullying and stigma associated with taking pills every day. Long-acting injectables taken every two months can help young people to lead a more normal life.”
She added, “The benefits of this form of treatment for adolescents is stronger than we have seen for adults. Previous trials in adults have shown only that injectables are no less effective than tablets.”
Pett said the findings supported wider availability of injectable treatment for adolescents. “Nine out of 10 adolescents with HIV live in Africa, yet currently this treatment is not accessible to them,” she said.
About 1.6 million adolescents aged 10 to 19 are living with HIV. Although there is currently no cure for HIV, antiretroviral treatment can enable people to live long, healthy lives and substantially reduce the risk of transmission.
Tags:#Hiv treatment#Long-acting injections#Adolescent health#Antiretroviral therapy#Viral suppression
Share Story:

More In Health